Novartis announced that its highly selective Bruton tyrosine kinase inhibitor Rhapsido® has been approved by the US FDA to treat symptomatic skin blemishes in adults who are unable to fully control symptoms after H1 antihistamines. This is also a new indication that the drug expanded after chronic spontaneous urticaria.

Zhitongcaijing · 4d ago
Novartis announced that its highly selective Bruton tyrosine kinase inhibitor Rhapsido® has been approved by the US FDA to treat symptomatic skin blemishes in adults who are unable to fully control symptoms after H1 antihistamines. This is also a new indication that the drug expanded after chronic spontaneous urticaria.